06/13/2026
MTHFR is just one enzyme in a long methylation cycle that includes COMT, MAOA, MTRR, BHMT, and others. How well each one works affects what happens after folate and B12 get converted into their active methyl forms.
Two downstream enzymes matter especially for the anxiety/sensitivity question:
COMT breaks down dopamine, norepinephrine, and adrenaline. Slow COMT variants mean those stimulating neurotransmitters stay in circulation longer — more caffeine sensitivity, more anxiety, more reactivity. These people often identify as "highly sensitive."
MAOA breaks down serotonin, dopamine, and norepinephrine. Slow variants can cause these to build up, contributing to mood reactivity, anger, and sleep issues.
Here's why this matters: methylated B-vitamins deliver pre-activated methyl donors directly into your system. If your downstream enzymes (COMT, MAOA) are slow, those methyl donors can't be processed and cleared at a normal rate — they build up. The result is exactly what the methylated stack is supposed to prevent: overstimulation, anxiety, racing thoughts, insomnia.
This is why some MTHFR carriers feel worse on methylated forms. It's not that their bodies don't recognize the vitamins — it's that their downstream chemistry can't keep up.
A heterozygous MTHFR carrier with slow COMT and slow MAOA is in particular trouble. They're only ~30% slower at folate conversion, so they don't need aggressive methyl support — but the flood of methyl donors swamps their already-slow downstream enzymes. The standard protocol makes their problem worse, not better.
This profile is more common than you'd think. Studies estimate 20–30% of the population carries slow COMT variants, with overlapping rates for slow MAOA. Combined with MTHFR (also common), that's a significant subset of people for whom the standard methylated protocol is actively counterproductive — even though they've been told it's exactly what they need.